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The fight against diabetes mellitus, the
third highest non-infectious killer
disease in South Africa (behind
ischaemic heart disease and cancer), will
be bolstered in December 2006 when
Cape Town hosts the World Diabetes
Congress.
Rated the biggest conference ever to
hit the Mother City, the 19th World
Diabetes Congress could attract as
many as 14 000 delegates and generate
R80 million for the local economy. More
importantly, it will enable collaboration
among the creators of the latest cutting
edge technology and procedures in
diabetes mellitus — and bring the
resource-rich organisations that back
them into our back yard.
Cure in sight?
This in a year in which the scientific
community is abuzz with news that a
multidisciplinary team at King’s College
Hospital has successfully achieved a
breakthrough in islet cell
transplantation in a type 1 diabetes
patient.
The breakthrough involved three
transplants of islet cells isolated from
cadaveric donor pancreases into a 61-
year-old patient — resulting in him no
longer needing insulin injections and
being completely free of hypoglycaemia.
A South African at the forefront of
pancreas transplantation and stem cell
research at Stellenbosch University,
Professor Don du Toit, affirmed the
British work as a breakthrough – adding
that local work held the potential to
expand therapy even further.
Professor Stephanie Amiel, a
consultant in diabetes at King’s College,
described the UK achievement as
‘hugely exciting. The implications are
enormous. Eventually, this could mean
the end of insulin dependence for all
type 1 diabetes sufferers.’
Transplantation drawbacks
In its current state of technology,
however, islet transplantation is
imperfect.
Says Amiel ‘We do not have enough
organ donors, therefore we cannot
extract enough islets to help all type 1
patients. More research needs to be
done to perfect the islet isolation
procedures and the drugs we use to
prevent rejection of the islets and
recurrence of the diabetes.’
The King’s College team can only
offer this treatment to patients in whom
conventional treatments are failing in a
major way. Amiel said the ultimate aim
was for all people with type 1 diabetes
to become eligible for islet
transplantation and free from insulin
dependence.
Professor Du Toit, who heads South
Africa’s only biotech laboratory (at
Stellenbosch University), said he
suspected that behind the King’s Cross
breakthrough was a new ability to
refine the yield per pancreas per gram
of wet tissue. ‘The problem was always
to isolate the 1% of islet cells from the
2% of ductal tissue and 97% of acinar
cells in the pancreas – you need about 
600 000 islet cells to reverse diabetes —
and then you still need
immunosuppression.’
Leap frog in the offing?
He believes that his current work on
progenitor stem cells regenerating the
pancreas holds the potential to
‘overtake’ the islet cell research.
‘Already others have shown that by
using the patient’s own bone marrow
progenitor cells, within a week patients’
insulin requirements have dropped by
90% and they can go on
antidiabetogenic tablets.’
Du Toit explained that a group in the
USA had grown beta progenitor cells by
expanding them in tissue culture for 3 -
6 weeks and then injected them into the
pancreas tail via the splenic artery and a
catheter ‘basically converting a type 1
diabetes patient into a type 2 diabetic’.
Historically, islet transplants have
only been partially successful, reducing
the amount of insulin required, but still
requiring regular injections.
Background
Five years ago surgeons at the
University of Alberta in Edmonton,
Canada, adjusted the combination of
immunosuppressive drugs used to
prevent rejection of the new cells and
achieved successful transplants in 8
patients. Since then, the Edmonton
Protocol, as it came to be known, has
been used, with some variations, on
about 500 patients worldwide. Most
patients, however, are using insulin
again, although not as much as they
needed before their transplants. 
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